Filing Flows › IGC Pharma (IGC) › Q3 2026
IGC Pharma (IGC) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 6, 2026
IGC Pharma (IGC) reported revenue of $328K for the third quarter 2026 (Q3 2026), +72% from a year earlier and +24% from the quarter before. Operating margin was -588.7%, net loss $2.0M (623.8% of revenue).
IGC Pharma, Q3 2026: revenue $328K (+72% year over year), operating margin -588.7%, net loss $2.0M, operating cash flow −$1.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $328K | +24% | +72% |
| Operating profit | −$1.9M | — | — |
| Net earnings | −$2.0M | — | — |
| Operating cash flow | −$1.4M | — | — |
What changed
Revenue was $328K in Q3 2026, up 72% year over year and up 24% from the previous quarter. White Labeling Services was the largest line at 98% of revenue. White Labeling Services added $168K year over year (up 110%), 123% of the total change. Wellness and Lifestyle declined 82%.
Gross margin was 18.6%, down 33.2 points from Q3 2025. Operating costs exceeded revenue by $1.9M, an operating margin of -588.7%. Operating expenses fell 34% while revenue rose 72%. The quarter ended with a net loss of $2.0M, narrower than the previous quarter's $2.9M loss.
Operating cash flow was −$1.4M. Non-cash charges added back $58K of depreciation and amortization. Working capital and other items added $571K.
Questions
What was IGC Pharma's revenue in the third quarter 2026?
IGC Pharma (IGC) reported revenue of $328K for the third quarter 2026 (Q3 2026), +72% from a year earlier and +24% from the quarter before.
Was IGC Pharma profitable in the third quarter 2026?
Operating loss was $1.9M (-588.7% of revenue) and net loss $2.0M.
Source: IGC Pharma 10-Q on SEC EDGAR.